Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck (MRK) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Merck (MRK) has delivered significantly stronger year-to-date and one-year price performance compared with Pfizer (PFE), reflecting robust momentum in recent market activity.
- Both companies operate in the pharmaceutical sector with major oncology and specialty portfolios, though Merck benefits from consistent Keytruda (pembrolizumab) franchise strength while Pfizer pursues broader pipeline diversification including new indications and formulations.
- Analyst sentiment has tilted positively toward Merck (MRK) with multiple price target increases in recent weeks, whereas Pfizer (PFE) maintains a more balanced rating profile amid ongoing loss-of-exclusivity considerations.
- Merck (MRK) trades near the upper end of its 52-week range with lower beta, indicating relative stability, while Pfizer (PFE) offers a substantially higher dividend yield.
- Upcoming second-quarter earnings releases for both stocks on or around August 4, 2026, represent a shared near-term catalyst that could influence relative positioning.
- Market positioning favors Merck (MRK) in terms of recent trend consistency and growth visibility, creating clear trade-offs versus Pfizer’s (PFE) income appeal and pipeline optionality.
Introduction
Merck (MRK) and Pfizer (PFE) represent two leading pharmaceutical companies whose stocks are frequently compared by investors seeking exposure to the healthcare sector. This analysis examines their relative performance, business profiles, and market dynamics in the current environment. The comparison is particularly relevant for traders monitoring momentum and stability as well as income-focused investors evaluating dividend yields and pipeline catalysts. By focusing on observable factors such as recent price behavior and sector positioning, the article provides a factual framework for assessing these stocks side by side.
MRK Overview and Recent Performance
Merck (MRK) is a global pharmaceutical company with a primary focus on oncology, vaccines, and animal health. Its flagship Keytruda therapy continues to drive revenue growth across multiple cancer indications. In recent market activity, the stock has shown strong upward momentum, closing near $130.20 on July 31, 2026, and trading close to its 52-week high. Year-to-date returns have reached approximately 25.5%, significantly outpacing broader market benchmarks. Recent developments include FDA approval of Lipfendra for hypercholesterolemia, positive data from HIV and oncology trials, and multiple analyst price target upgrades. These factors have supported constructive sentiment and consistent trend behavior in recent weeks.
PFE Overview and Recent Performance
Pfizer (PFE) is a major biopharmaceutical company with established positions in oncology, vaccines, and internal medicine. The company maintains a diversified pipeline that includes updates across rare diseases, inflammation, and infectious disease areas. In recent market activity, shares have traded around $25.01 as of July 31, 2026, within the middle of their 52-week range. Performance over the past year has been more modest, with gains near 4.6%. Notable recent developments include positive Phase 3 results for LITFULO in vitiligo, priority review for a prostate cancer combination, and continued progress on obesity and COVID-19 vaccine adaptations. These pipeline updates have contributed to measured sentiment amid a higher dividend yield environment.
Trending AI Robots
Trending AI Robots showcases a curated selection of Tickeron’s extensive collection of AI trading bots. Tickeron offers hundreds of AI-powered trading bots designed to trade thousands of different tickers across equities, options, and other instruments. Only those demonstrating the strongest alignment with prevailing market conditions, robust risk-adjusted statistics, and consistent historical performance earn placement in the Trending section. Available bots span a wide range of trading styles, timeframes, and performance metrics, with many exhibiting win rates between 55% and 75% and varying Sharpe ratios depending on their specific strategies. All bots operate with distinct parameters and ticker universes. Review the full selection on the Trending AI Robots page for details suited to individual objectives.
Head-to-Head Comparison
Merck (MRK) and Pfizer (PFE) both derive substantial revenue from innovative pharmaceuticals yet differ in growth drivers and risk profiles. Merck’s concentrated strength in oncology via Keytruda provides more predictable revenue visibility, supporting stronger recent price momentum and analyst upgrades. Pfizer maintains broader diversification, including vaccine platforms and emerging areas such as obesity and dermatology, which offer additional upside potential but also introduce execution variability. In recent weeks, Merck has demonstrated superior trend consistency and stability with lower beta, while Pfizer offers materially higher dividend yield, appealing to income-oriented strategies. Sector exposure remains comparable within healthcare, though Merck’s positioning near 52-week highs contrasts with Pfizer’s mid-range trading levels. Market sentiment has favored Merck’s recent catalysts, creating a trade-off between momentum stability and yield-plus-pipeline optionality.
Tickeron AI Verdict
Based on observable factors including trend consistency, stability metrics, and positive catalyst flow in recent market activity, Tickeron’s AI would likely assign a higher probabilistic preference to Merck (MRK) over Pfizer (PFE) at present. The stronger price performance, repeated analyst support, and pipeline de-risking events provide a clearer near-term positioning edge. This assessment remains probabilistic and subject to shifts following upcoming earnings and broader market developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 3 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- MRK’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 5 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +5.65% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | PFE | MRK / PFE | |
| Capitalization | 335B | 153B | 219% |
| EBITDA | 19.4B | 17.2B | 113% |
| Gain YTD | 30.943 | 13.144 | 235% |
| P/E Ratio | 108.67 | 35.25 | 308% |
| Revenue | 65.8B | 63.3B | 104% |
| Total Cash | N/A | N/A | - |
| Total Debt | 49.1B | 63.7B | 77% |
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 40 | 100 | |
SMR RATING 1..100 | 47 | 76 | |
PRICE GROWTH RATING 1..100 | 9 | 29 | |
P/E GROWTH RATING 1..100 | 2 | 7 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (61). This means that PFE’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as PFE (76). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Price Growth Rating (9) in the Pharmaceuticals Major industry is in the same range as PFE (29). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as PFE (7). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 54% | N/A |
| TrendWeek ODDS (%) | 2 days ago 57% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 48% |
| Advances ODDS (%) | 2 days ago 57% | 9 days ago 52% |
| Declines ODDS (%) | 17 days ago 51% | 4 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 45% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.04% | ||
| BMY - PFE | 57% Loosely correlated | -1.27% | ||
| MRK - PFE | 55% Loosely correlated | +0.21% | ||
| AMGN - PFE | 53% Loosely correlated | -0.63% | ||
| NVS - PFE | 51% Loosely correlated | -0.55% | ||
| BIIB - PFE | 51% Loosely correlated | -0.39% | ||
More | ||||